Logo

BBIO

BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc. • NASDAQ
$72.01 ▲ 0.40% (+0.29)
Market Cap $13.72 B
52w High $72.28
52w Low $25.34
Dividend Yield 0%
P/E -17.1
Volume 449.28K
Outstanding Shares 190.51M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $120.7M ▲ $259.336M ▲ $-182.743M ▼ -151.403% ▲ $-0.96 ▼ $-173.345M ▼
Q2-2025 $110.565M ▼ $241.19M ▲ $-181.903M ▼ -164.521% ▼ $-0.95 ▼ $-142.704M ▼
Q1-2025 $116.633M ▲ $218.366M ▼ $-167.422M ▲ -143.546% ▲ $-0.88 ▲ $-126.183M ▲
Q4-2024 $5.882M ▲ $229.825M ▲ $-265.05M ▼ -4.506K% ▲ $-1.4 ▼ $-235.048M ▼
Q3-2024 $2.732M $193.884M $-162.04M -5.931K% $-0.86 $-139.655M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $645.942M ▼ $998.25M ▼ $2.921B ▲ $-1.923B ▼
Q2-2025 $757.341M ▲ $1.08B ▲ $2.859B ▲ $-1.788B ▼
Q1-2025 $540.599M ▼ $881.638M ▼ $2.52B ▲ $-1.648B ▼
Q4-2024 $681.101M ▲ $919.338M ▲ $2.377B ▲ $-1.468B ▼
Q3-2024 $266.324M $664.977M $1.883B $-1.23B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-182.743M ▲ $-109.574M ▼ $4.464M ▲ $-894K ▼ $-106.325M ▼ $-110.044M ▼
Q2-2025 $-183.758M ▼ $-80.681M ▲ $-13.002M ▼ $302.041M ▲ $208.358M ▲ $-85.775M ▲
Q1-2025 $-169.608M ▲ $-199.235M ▼ $-1.595M ▲ $60.328M ▼ $-140.502M ▼ $-200.83M ▼
Q4-2024 $-267.389M ▼ $-195.326M ▼ $-3.237M ▼ $473.931M ▲ $275.368M ▲ $-198.563M ▼
Q3-2024 $-164.254M $-180.566M $38.226M $707K $-141.633M $-182.298M

Revenue by Products

Product Q1-2023Q1-2025Q2-2025Q3-2025
License and Service
License and Service
 $0 ▲$0 ▲$0 ▲$10.00M ▲
Product
Product
 $0 ▲$0 ▲$0 ▲$110.00M ▲
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲
Net Product Revenue
Net Product Revenue
 $0 ▲$40.00M ▲$70.00M ▲$0 ▼
Royalty Revenue
Royalty Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement BridgeBio is still very much a development-stage company: revenue is tiny and irregular, while operating expenses remain very high. Losses have been large and consistent over the last several years, reflecting heavy investment in research and clinical trials rather than any broad commercial scale yet. There are some signs that losses are not rapidly worsening, but the business is clearly not close to break-even and depends on future product approvals and launches to change that picture.

Balance Sheet

Balance Sheet The balance sheet is dominated by cash on one side and sizable debt on the other, with very little in the way of tangible operating assets. Accounting equity has turned deeply negative, which simply reflects that cumulative losses and financing structure have outpaced contributed capital. This setup is common in late-stage biotech, but it leaves the company financially levered and dependent on either successful drug commercialization or additional financing to comfortably manage its obligations over time.

Cash Flow

Cash Flow Cash flow from operations has been steadily negative, driven by ongoing R&D and clinical spending, while capital spending on physical assets is minimal. Free cash flow is therefore meaningfully negative, underscoring that BridgeBio consumes cash rather than generates it at this stage. The current cash balance provides a runway, but without a sharp improvement in commercial cash inflows or fresh external funding, the company will eventually need to revisit its capital structure.

Competitive Edge

Competitive Edge BridgeBio has carved out a differentiated position by focusing on genetically defined, often rare diseases and by running a broad portfolio rather than betting on a single drug. Its hub-and-spoke structure allows highly specialized teams to advance specific programs, while central functions support development and commercialization. The pipeline includes both approved products and several late-stage candidates, which gives it more shots on goal than a typical single-asset biotech. At the same time, it faces tough competition from larger pharmaceutical companies in some key areas and must prove it can execute commercially, not just scientifically.

Innovation and R&D

Innovation and R&D The company’s core strength lies in its systematic approach to genetically validated targets and its willingness to run many programs in parallel. R&D remains the largest use of resources, with a clear bias toward late-stage, high-impact programs in rare diseases and genetic conditions. The internal discovery engine and partnerships with academia help keep the pipeline refreshed, while the portfolio design spreads scientific risk across many assets. The flip side is that sustained high R&D spending keeps financial losses elevated until multiple programs successfully reach the market.

Summary

BridgeBio is a high-science, high-risk, high-upside biotechnology story: it has a deep and innovative pipeline, a distinctive operating model, and a clear focus on genetic diseases, but it is still far from financial self-sufficiency. The company runs sizable recurring losses, carries meaningful debt, and relies on cash reserves and external capital to fund its ambitions. Its future financial health will hinge on the success of key late-stage programs, especially the transition of acoramidis and other near-term candidates from clinical assets into meaningful, recurring commercial revenue streams.

NEWS

November 25, 2025 · 7:30 AM UTC

BridgeBio to Participate in December Investor Conferences

Read more

November 19, 2025 · 4:01 PM UTC

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more

November 8, 2025 · 10:41 AM UTC

Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations

Read more

November 7, 2025 · 1:00 PM UTC

National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry

Read more

November 4, 2025 · 7:30 AM UTC

BridgeBio to Participate in November Investor Conferences

Read more